Analyst Reco. Johnson & Johnson Santiago S.E.

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 20:09:10 03/06/2024 BST			5-day change	1st Jan Change
148 ^USD	-0.21%		0.00%	-6.76%

12:44pm	J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	RE
12:15pm	J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	RE

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	05-01	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	04-25	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	04-22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	04-18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	04-18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	04-18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	04-17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	04-17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	04-17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	04-17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	04-16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	04-09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	04-05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	04-04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	01-24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	01-24	MT
The market awaits the BCE meeting and earnings reports	01-23
The start of a new bull market?	01-22
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	01-09	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	01-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm